The development of androgen-independent prostate cancer

@article{Feldman2001TheDO,
  title={The development of androgen-independent prostate cancer},
  author={B. Feldman and D. Feldman},
  journal={Nature Reviews Cancer},
  year={2001},
  volume={1},
  pages={34-45}
}
The normal prostate and early-stage prostate cancers depend on androgens for growth and survival, and androgen ablation therapy causes them to regress. Cancers that are not cured by surgery eventually become androgen independent, rendering anti-androgen therapy ineffective. But how does androgen independence arise? We predict that understanding the pathways that lead to the development of androgen-independent prostate cancer will pave the way to effective therapies for these, at present… Expand
Progression of prostate cancer: multiple pathways to androgen independence.
TLDR
The multiple pathways that have been shown to promote androgen independence are reviewed, including a recently described mechanism that involves androgen receptor proteolysis to a constitutively active ligand-independent isoform. Expand
Mechanisms leading to the development of hormone-resistant prostate cancer.
TLDR
The mechanisms by which hormone resistance develops, including the reactivation of androgen receptor during androgen deprivation therapy, the role of cancer stem cells, and the emergence of epithelial-mesenchymal transition cells, which have increased metastatic potential are focused on. Expand
Androgen Action in Prostate Cancer
TLDR
This review summarizes the current information regarding the role of androgens in prostate cancer and recommends androgen ablation as the preferred initial therapeutic approach for the treatment of advanced prostate cancer patients. Expand
Androgen-independent prostate cancer: target evolution and disease dynamics
TLDR
Novel therapies directed at the biological mechanisms of androgen independent growth, including adrenal androgens, the insulin-like growth factors and transforming growth factor-beta, are being pursued in clinical trials. Expand
Biology of castration-recurrent prostate cancer.
TLDR
The diversity of mechanisms used for growth by castration-recurrent prostate cancer is reviewed, using several mechanisms that remain dependent on androgen-receptor signaling in most cases. Expand
Mechanisms of androgen-refractory prostate cancer.
TLDR
When prostate cancer is localized in the prostate, the treatment of choice is prostatectomy or irradiation, however, when the tumor relapses or is already metastatic at diagnosis, therapy is problematic. Expand
Upregulation of the Androgen Receptor during Prostate Cancer Progression
TLDR
It is reported that the androgen receptor is consistently upregulated as hormone sensitive prostate cancer changes to a hormone refractory state and that this change is intricately involved during the development of resistance to androgen ablation therapy. Expand
Molecular basis for androgen independency in prostate cancer
TLDR
This review will try to summarize the knowledge of the genetic events governing the conversion to androgen independency in prostate tumorigenesis. Expand
Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer
TLDR
It is estimated that during 2005, ∼232,090 new cases of prostate cancer will be diagnosed in the United States and 30,350 menwill be diagnosed with prostate cancer. Expand
Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity
TLDR
The role of the androgen receptor in the progression of androgen‐dependent human prostate cancer cells to androgen-independent and androgens‐insensitive phenotypes is unclear. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 108 REFERENCES
Expression, structure, and function of androgen receptor in advanced prostatic carcinoma
TLDR
The presence of mutant androgen receptors in a portion of prostate cancers and receptor activation in the absence of androgen or in the presence of low androgen concentrations is discussed. Expand
LNCaP progression model of human prostate cancer: Androgen‐independence and osseous metastasis
TLDR
One of the sublines, C4‐2, was found to be AI, highly tumorigenic, and metastatic, having a proclivity for metastasis to the bone. Expand
A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy.
TLDR
A majority of recurrent prostate cancers express high levels of the androgen receptor and two nuclear receptor coactivators, transcriptional intermediary factor 2 and steroid receptors coactivator 1, and this work provides a molecular basis for this activation and suggests a general mechanism for recurrent prostate cancer growth. Expand
Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor
TLDR
It is shown that in CaP cells from a patient who failed androgen ablation therapy, a doubly mutated AR functioned as a high-affinity cortisol/cortisone receptor (ARccr), demonstrating a previously unknown mechanism for the androgen-independent growth of advanced CaP. Expand
Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process.
TLDR
It is concluded that prostate cancers contain heterogeneous mixtures of cells that vary in their dependence on androgen for growth and survival and that treatment with antiandrogen therapy provides selective pressure and alters the relative frequency of these cells, thereby leading to outgrowths of androgen-independent cancers. Expand
Her-2-neu expression and progression toward androgen independence in human prostate cancer.
TLDR
Her-2-neu expression appears to increase with progression to androgen independence, and therapeutic targeting of this tyrosine kinase in prostate cancer may be warranted. Expand
Collocation of androgen receptor gene mutations in prostate cancer.
TLDR
Missense mutations in the AR gene identified in prostate cancer that collocate to discrete regions of the receptor contribute to altered androgen signaling and provide a potential mechanism to explain the reemergence of tumor growth during the course of hormone ablation therapies. Expand
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
TLDR
Findings demonstrate that AR mutations occur in response to strong selective pressure from flutamide treatment, and these mutations responded to subsequent treatment with bicalutamide, an AR antagonist that blocks the mutant ARs. Expand
A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase
TLDR
By modulating the response to low doses of androgen, a tyrosine kinase receptor can restore androgen receptor function to prostate cancer cells, a finding directly related to the clinical progression of prostate cancer. Expand
Prostate cancer and the androgen receptor: strategies for the development of novel therapeutics.
  • L. Mendelsohn
  • Biology, Medicine
  • Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques
  • 2000
TLDR
Progress in this direction has been realized with the recent synthesis of non-steroidal androgen agonists that may have tissue-selective effects. Expand
...
1
2
3
4
5
...